indigestion with tirzepatide Dosing Managing GI Discomfort on GLP-1s:

Risk: Realized prices fell 13% in Q1 2026 due to rebate adjustments and market-access agreements, and Mounjaro's NRDL addition in China is pressuring international pricing

o Diarrhea: Another common side effect that might be transient

The upper arm The back of the upper arm, specifically the triceps area, is the third approved injection site

Trulicity sales in 2015 reached $248.7 million and continued to climb to $925.5 million in 2016 and to $2030 million in 2017, taking significant market share away from Victoza (Figure 7, Table 5) [187-189]

They are clinically tested and proven to deliver significant results

For investors tracking CPSE:NOVO B, this India generic wave arrives after a mixed share price pattern, with the stock at DKK241.8 and a 19.7% gain over five years, but a 26.8% decline year to date and a 39.8% decline over one year